Skip to content

Bladder Cancer Health Center

Medical Reference Related to Bladder Cancer

  1. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (09 / 26 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.This summary was comprehensively reviewed and reformatted.This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  2. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Bladder Cancer

    Recurrent bladder cancer is cancer that has recurred (come back) after it has been treated. The cancer may come back in the bladder or in other parts of the body.

  3. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Bladder Cancer

    Nonmuscle-invasive Bladder CancerTreatment of nonmuscle-invasive bladder cancers (Ta, Tis, T1) is based on risk stratification. Essentially all patients are initially treated with a transurethral resection (TUR) of the bladder tumor followed by a single immediate instillation of intravesical chemotherapy (mitomycin C is typically used in the United States).[1,2,3,4,5,6,7]Subsequent therapy after the treatment above is based on risk and typically consists of one of the following:[6,7,8,9]Surveillance for relapse or recurrence (typically used for tumors with low risk of recurrence or progression).A minimum of 1 year of intravesical treatments with bascillus Calmette-Guérin (BCG) plus surveillance for relapse (typically used for tumors at intermediate or high risk of progression to muscle-invasive disease).Additional intravesical chemotherapy (typically used for tumors with a high risk of recurrence but low risk of progression to muscle-invasive disease).Muscle-invasive

  4. Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062925-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Urethral Cancer Treatment

  5. Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

  6. Bladder Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Bladder Cancer Treatment

    Standard Treatment Options for Stage I Bladder CancerPatients with stage I bladder tumors are unlikely to die from bladder cancer, but the tendency for new tumor formation is high. In a series of patients with Ta or T1 tumors who were followed for a minimum of 20 years or until death, the risk of bladder recurrence after initial resection was 80%.[1] Of greater concern than recurrence is the risk of progression to muscle-invasive, locally-advanced, or metastatic bladder cancer. While progression is rare for low-grade tumors, it is common among high-grade cancers. One series of 125 patients with TaG3 cancers followed for 15 to 20 years reported that 39% progressed to more advanced stage disease, while 26% died of urothelial cancer. In comparison, among 23 patients with TaG1 tumors, none died and only 5% progressed.[2] Risk factors for recurrence and progression include the following:[2,3,4,5,6]High-grade disease.Presence of carcinoma in situ.Tumor larger

  7. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview

    There are different types of treatment for patients with bladder cancer. Different types of treatment are available for patients with bladder cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment. Four types of standard treatment are used:Surgery One of the following types of surgery may be done: Transurethral resection (TUR) with fulguration: Surgery in which a cystoscope (a thin lighted tube) is inserted into the bladder through the urethra. A tool with a small wire loop on the end is then used

  8. Bladder Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000062705-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Bladder Cancer Treatment

  9. Urethral Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Urethral Cancer

    Prognosis and treatment decisions are both determined by:[1]The anatomical location of the primary tumor.The size of the tumor.The stage of the cancer.The depth of invasion of the tumor.The histology of the primary tumor is of less importance in estimating response to therapy and survival.[2] Endoscopic examination, urethrography, and magnetic resonance imaging are useful in determining the local extent of the tumor.[3,4]Distal Urethral CancerThese lesions are often superficial. Female: Lesions of the distal third of the urethra.Male: Anterior, or penile, portion of the urethra, including the meatus and pendulous urethra.Proximal Urethral CancerThese lesions are often deeply invasive. Female: Lesions not clearly limited to the distal third of the urethra.Male: Bulbomembranous and prostatic urethra.Urethral Cancer Associated with Invasive Bladder CancerApproximately 5% to 10% of men with cystectomy for bladder cancer may have or may develop urethral cancer distal to the urogenital

  10. Bladder and Other Urothelial Cancers Screening (PDQ®): Screening - Health Professional Information [NCI] - Description of the Evidence

    Incidence and MortalityBladder cancer is the fourth most commonly diagnosed malignancy in men in the United States. It is estimated that 72,570 new cases of bladder cancer are expected to occur in the United States in 2013.[1]Bladder cancer is diagnosed almost twice as often in whites as in blacks of either sex. The incidence of bladder cancer among other ethnic and racial groups in the United States falls between that of blacks and whites. The incidence of bladder cancer increases with age.[2]Since the 1950s, the incidence of bladder cancer has risen by approximately 50%. It is to be anticipated that, with the aging of the U.S. population, this trend will continue. There has been a decrease of approximately 33% in bladder cancer mortality during the same interval (National Cancer Institute's Surveillance, Epidemiology, and End Results program, 1973–1997). It is estimated that 15,210 Americans will die of bladder cancer in 2013.[1]The age-adjusted mortality from

Displaying 31 - 40 of 96 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

Today on WebMD

bladder cancer x-ray
Do you know the warning signs?
man with a doctor
Our health check will steer you in the right direction.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
Lifestyle Tips for Depression Slideshow
SLIDESHOW
Bladder Sparing Cancer Treatment
VIDEO
 
Vitamin D
SLIDESHOW
Pets Improve Your Health
SLIDESHOW
 

WebMD Special Sections